NRXBF: Critical Year Starts with Company in Good Shape
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
390 Views
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
237 Views
NRXBF: US Investors Should Pay Attention
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
206 Views
NRXBF: New Test Results Opens Potential New Market
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
265 Views
NRXBF: Company Remains on Track
NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...
413 Views